BCVA, anatomic improvements found with OPT-302 combination therapy for PCV

Video
Conference|ARVO

At ARVO 2022, Dr Jason S. Slakter presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

Emily Kaiser, editor of Modern Retina™, sits down with Dr Jason S. Slakter to discuss his ARVO 2022 presentation, “Efficacy and Safety of OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy.” OPT-302 (Opthea Limited) 2 mg combination therapy results indicated a safety profile consistent with the standard of care anti-VEGF-A monotherapy, but also indicated superior improvements in best-corrected visual acuity (BCVA) and anatomic improvements compared to monthly ranibizumab (Lucentis®) monotherapy in patients with polypoidal choroidal vasculopathy (PCV).

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
Related Content
Image credit: ©Vitechek – stock.adobe.com

Going beyond the clinical setting in ophthalmic mentorship

May 9th 2024
Article

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

A single tear on a person's face. Image credit: ©Chepko Danil – stock.adobe.com

ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease

May 7th 2024
Article

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

A young girl undergoes an eye exam. Image credit: ©Alexis S/peopleimages.com – stock.adobe.com

ARVO 2024: Children with CVI experience lower vision-specific quality of life, study results indicate

May 6th 2024
Article

Investigators say children with cortical/cerebral visual impairment experience markedly lower vision-specific quality of life

A child has their blood sugar tested using a digital glucometer. Image credit: ©Africa Studio – stock.adobe.com

ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes

May 5th 2024
Article

Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy

A group of children run outside. Image credit: ©JackF – stock.adobe.com

ARVO 2024: CHAMP phase 3 trial shows myopia controlled by low-dose atropine 0.01% over 4-year course

May 5th 2024
Article

This study also investigated the development of myopia rebound when dosing was discontinued

Susana Chung, OD, PhD, talks about her ARVO presentation titled "How similar is reading with central vision loss to reading in normal peripheral vision?"

ARVO 2024: New research indicates the need for a new approach to central vision loss

May 5th 2024
Article

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

© 2024 MJH Life Sciences

All rights reserved.